Perimenopause Vaginal Dryness: Why It Happens and What Helps

DEFINITION

Genitourinary Syndrome of Menopause (GSM)

The clinical term replacing 'vaginal atrophy' — encompassing vaginal dryness, irritation, burning, dyspareunia (painful sex), urinary urgency, frequency, and recurrent UTIs caused by declining estrogen's effect on vaginal, vulvar, and urinary tract tissue. These symptoms do not resolve without treatment.

DEFINITION

Vaginal epithelium

The cellular lining of the vaginal walls. Highly responsive to estrogen, which maintains cell thickness, glycogen content (supporting healthy bacterial flora), lubrication, and elasticity. Declining estrogen causes the epithelium to thin, lose glycogen, and produce less lubrication, resulting in dryness, irritation, and increased pH.

Estrogen and Vaginal Tissue

The vaginal epithelium contains a high density of estrogen receptors. Throughout reproductive life, estrogen maintains vaginal tissue health: it keeps cells thick and well-glycogenated, supports healthy vaginal bacterial flora (Lactobacillus species), maintains lubrication, and preserves elasticity and pH balance.

As estrogen declines in perimenopause, vaginal tissue changes. The epithelium thins, glycogen content falls, lubrication decreases, vaginal pH rises (becoming less acidic), and Lactobacillus species decline. This makes the tissue more vulnerable to irritation, infection, and pain with penetration.

Why GSM Differs From Hot Flashes

Hot flashes and night sweats are vasomotor symptoms driven by hypothalamic thermoregulation changes. For many women, these improve significantly in post-menopause as the transition completes.

GSM is different. It is a progressive tissue change — without treatment, vaginal and vulvar tissue continues to thin and atrophy post-menopause. Early intervention produces better tissue restoration than treating advanced atrophy. This is why GSM warrants proactive discussion rather than waiting until symptoms become severe.

Treatment Options

Local vaginal estrogen is the primary evidence-based treatment. Available as creams, pessaries, and sustained-release rings. Minimal systemic absorption. Safe for most women including those who cannot use systemic HRT.

Vaginal moisturisers: Non-hormonal, used regularly (2-3 times per week), provide symptom relief. Reduce pH and improve tissue hydration. A long-term complement to treatment.

Lubricants: For sexual activity. Silicone-based lubricants last longer than water-based. Important for preventing pain and microtrauma during sex.

Systemic HRT: Treats GSM alongside other symptoms but delivers higher estrogen doses than local treatment. Local estrogen is preferred when GSM is the primary concern.